Skip to content

Study · Systematic review · 2024

12 results

Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials.

Nalisa DL, Cuboia N, Dyab E, Jackson IL, Felix HJ, Shoki P, Mubiana M, Oyedeji-Amusa M, Azevedo L, Jiang H

Frontiers in endocrinology14 Feb 2024Cited by 23 (Europe PMC)

PMID38440786 (opens in a new tab)PMCIDPMC10911117 (opens in a new tab)DOI10.3389/fendo.2024.1309118 (opens in a new tab)PepBankPUB-38440786
Download PDFPubMedAsk about this study
Jump to 12 results

Summary

BackgroundOverweight and obesity are increasing global public health problems. Mazdutide is a new dual agonist drug that can potentially reduce weight and blood glucose levels simultaneously. However, the synthesis of evidence on the efficacy and safety of this drug is scarce. Therefore, this study aimed to synthesize evidence on the efficacy and safety of Mazdutide compared to placebo on weight reduction among adults with and without diabetes.MethodsWe conducted a systematic review and meta-analysis of randomized controlled trials (RCTs). Data were retrieved from six electronic databases: PubMed, Web of Science, Scopus, Cochrane Library, ClinicalTrial.gov, and Google Scholar, and manually searched from the included references. The data were synthesized using a random effect model. This analysis was performed in the R programming language using the Meta package.ResultsA total of seven RCTs involving 680 participants were included in this study. Mazdutide was more effective in reducing body weight (mean difference [MD]= -6.22%, 95% confidence interval [CI]: -8.02% to -4.41%, I2 = 90.0%), systolic blood pressure (MD = -7.57 mmHg, 95% CI: -11.17 to -3.98 mmHg, I2 = 46%), diastolic blood pressure (MD = -2.98 mmHg, 95% CI: -5.74 to -0.22 mmHg, I2 = 56%), total cholesterol (MD = -16.82%, 95% CI: -24.52 to -9.13%, I2 = 61%), triglycerides (MD = -43.29%, 95% CI: -61.57 to -25.01%, I2 = 68%), low-density lipoprotein (MD= -17.07%, 95% CI: -25.54 to -8.60%, I2 = 53%), and high-density lipoprotein (MD = -7.54%, 95% CI: -11.26 to -3.83%, I2 = 0%) than placebo. Mazdutide was associated with reduced hemoglobin A1c (HbA1c) and fasting plasma glucose in participants with type 2 diabetes. In the subgroup and meta-regression analyses, weight reduction was more significant in non-diabetics compared to diabetics, and in those who received a longer treatment duration (24 weeks) than in those on shorter durations (12-20 weeks). Participants who received Mazdutide had a higher risk of transient mild or moderate gastrointestinal side effects.ConclusionMazdutite appears to be effective in weight reduction among patients with and without diabetes, and it has an advantage over other associated comorbidities. However, it was associated with mild or moderate gastrointestinal side effects.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=403859, identifier CRD42023403859.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a meta-analysis of seven RCTs in adults with and without diabetes, mazdutide reduced body weight more than placebo (mean difference -6.22%).

    In plain wordsIn a pooled analysis of trials, mazdutide lowered body weight more than placebo.

    Peptide
    Mazdutide
    Outcome
    DecreaseBody weight change (pooled)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference body weight
    −6.22%
    mazdutide vs placebo

    Source sentences

    Summary
    Mazdutide was more effective in reducing body weight (mean difference [MD]= -6.22%, 95% confidence interval [CI]: -8.02% to -4.41%, I2 = 90.0%)
    1 context sentence
    Summary · context
    A total of seven RCTs involving 680 participants were included in this study.
  2. 02HumanSystematic reviewEfficacy outcome

    In a meta-analysis of seven RCTs, mazdutide lowered systolic blood pressure more than placebo (mean difference -7.57 mmHg).

    In plain wordsIn a pooled analysis of trials, mazdutide lowered systolic blood pressure more than placebo.

    Peptide
    Mazdutide
    Outcome
    DecreaseSystolic blood pressure (pooled)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Mean difference systolic blood pressure
    −7.57 mmHg
    mazdutide vs placebo

    Source sentences

    Summary
    systolic blood pressure (MD = -7.57 mmHg, 95% CI: -11.17 to -3.98 mmHg, I2 = 46%)
    1 context sentence
    Summary · context
    A total of seven RCTs involving 680 participants were included in this study.
  3. 03HumanSystematic reviewEfficacy outcome

    In a meta-analysis of seven RCTs, mazdutide lowered diastolic blood pressure more than placebo (mean difference -2.98 mmHg).

    In plain wordsIn a pooled analysis of trials, mazdutide lowered diastolic blood pressure more than placebo.

    Peptide
    Mazdutide
    Outcome
    DecreaseDiastolic blood pressure (pooled)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Mean difference diastolic blood pressure
    −2.98 mmHg
    mazdutide vs placebo

    Source sentences

    Summary
    diastolic blood pressure (MD = -2.98 mmHg, 95% CI: -5.74 to -0.22 mmHg, I2 = 56%)
    1 context sentence
    Summary · context
    A total of seven RCTs involving 680 participants were included in this study.
  4. 04HumanSystematic reviewEfficacy outcome

    In a meta-analysis of seven RCTs, mazdutide lowered total cholesterol more than placebo (mean difference -16.82%).

    In plain wordsIn a pooled analysis of trials, mazdutide lowered total cholesterol more than placebo.

    Peptide
    Mazdutide
    Outcome
    DecreaseTotal cholesterol (pooled)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference total cholesterol
    −16.82%
    mazdutide vs placebo

    Source sentences

    Summary
    total cholesterol (MD = -16.82%, 95% CI: -24.52 to -9.13%, I2 = 61%)
    1 context sentence
    Summary · context
    A total of seven RCTs involving 680 participants were included in this study.
  5. 05HumanSystematic reviewEfficacy outcome

    In a meta-analysis of seven RCTs, mazdutide lowered triglycerides more than placebo (mean difference -43.29%).

    In plain wordsIn a pooled analysis of trials, mazdutide lowered triglycerides more than placebo.

    Peptide
    Mazdutide
    Outcome
    DecreaseTriglycerides (pooled)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference triglycerides
    −43.29%
    mazdutide vs placebo

    Source sentences

    Summary
    triglycerides (MD = -43.29%, 95% CI: -61.57 to -25.01%, I2 = 68%)
    1 context sentence
    Summary · context
    A total of seven RCTs involving 680 participants were included in this study.
  6. 06HumanSystematic reviewEfficacy outcome

    In a meta-analysis of seven RCTs, mazdutide lowered low-density lipoprotein cholesterol more than placebo (mean difference -17.07%).

    In plain wordsIn a pooled analysis of trials, mazdutide lowered LDL cholesterol more than placebo.

    Peptide
    Mazdutide
    Outcome
    DecreaseLDL cholesterol (pooled)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference LDL
    −17.07%
    mazdutide vs placebo

    Source sentences

    Summary
    low-density lipoprotein (MD= -17.07%, 95% CI: -25.54 to -8.60%, I2 = 53%)
    1 context sentence
    Summary · context
    A total of seven RCTs involving 680 participants were included in this study.
  7. 07HumanSystematic reviewEfficacy outcome

    In a meta-analysis of seven RCTs, mazdutide lowered high-density lipoprotein cholesterol more than placebo (mean difference -7.54%).

    In plain wordsIn a pooled analysis of trials, mazdutide lowered HDL cholesterol more than placebo.

    Peptide
    Mazdutide
    Outcome
    DecreaseHDL cholesterol (pooled)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference HDL
    −7.54%
    mazdutide vs placebo

    Source sentences

    Summary
    high-density lipoprotein (MD = -7.54%, 95% CI: -11.26 to -3.83%, I2 = 0%)
    1 context sentence
    Summary · context
    A total of seven RCTs involving 680 participants were included in this study.
  8. 08HumanSystematic reviewEfficacy outcome

    In a meta-analysis of participants with type 2 diabetes, mazdutide was associated with reduced HbA1c.

    In plain wordsIn a pooled analysis of people with type 2 diabetes, mazdutide was linked to lower HbA1c.

    Peptide
    Mazdutide
    Outcome
    DecreaseHbA1c in type 2 diabetes (pooled)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mazdutide was associated with reduced hemoglobin A1c (HbA1c) and fasting plasma glucose in participants with type 2 diabetes.
    1 context sentence
    Summary · context
    A total of seven RCTs involving 680 participants were included in this study.
  9. 09HumanSystematic reviewEfficacy outcome

    In a meta-analysis of participants with type 2 diabetes, mazdutide was associated with reduced fasting plasma glucose.

    In plain wordsIn a pooled analysis of people with type 2 diabetes, mazdutide was linked to lower fasting blood glucose.

    Peptide
    Mazdutide
    Outcome
    DecreaseFasting plasma glucose in type 2 diabetes (pooled)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mazdutide was associated with reduced hemoglobin A1c (HbA1c) and fasting plasma glucose in participants with type 2 diabetes.
    1 context sentence
    Summary · context
    A total of seven RCTs involving 680 participants were included in this study.
  10. 10HumanSystematic reviewEfficacy outcome

    In subgroup analysis, weight reduction with mazdutide was more significant in participants without diabetes than in those with diabetes.

    In plain wordsIn a pooled analysis, mazdutide led to more weight loss in people without diabetes than in people with diabetes.

    Peptide
    Mazdutide
    Outcome
    Not applicableWeight reduction in non-diabetics versus diabetics
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the subgroup and meta-regression analyses, weight reduction was more significant in non-diabetics compared to diabetics, and in those who received a longer treatment duration (24 weeks) than in those on shorter durations (12-20 weeks).
    1 context sentence
    Summary · context
    A total of seven RCTs involving 680 participants were included in this study.
  11. 11HumanSystematic reviewEfficacy outcome

    In meta-regression, weight reduction with mazdutide was more significant after a longer treatment duration (24 weeks) than after shorter durations (12-20 weeks).

    In plain wordsIn a pooled analysis, longer mazdutide treatment (24 weeks) led to more weight loss than shorter treatment (12-20 weeks).

    Peptide
    Mazdutide
    Outcome
    Not applicableWeight reduction by treatment duration
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the subgroup and meta-regression analyses, weight reduction was more significant in non-diabetics compared to diabetics, and in those who received a longer treatment duration (24 weeks) than in those on shorter durations (12-20 weeks).
    1 context sentence
    Summary · context
    A total of seven RCTs involving 680 participants were included in this study.
  12. 12HumanSystematic reviewSafety outcome

    In a meta-analysis, participants who received mazdutide had a higher risk of transient mild or moderate gastrointestinal side effects than those on placebo.

    In plain wordsIn a pooled analysis, mazdutide caused more mild or moderate stomach and bowel side effects than placebo.

    Peptide
    Mazdutide
    Outcome
    IncreaseGastrointestinal side effects (pooled)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Participants who received Mazdutide had a higher risk of transient mild or moderate gastrointestinal side effects.
    1 context sentence
    Summary · context
    A total of seven RCTs involving 680 participants were included in this study.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.